Lin-Hong Ye1,2,3,4, Yi Cai1,2,3,4, Xuan Shi1,2,3,4, Ian Yat Hin Wong5, Jin-Feng Qu1,2,3,4, Ming-Wei Zhao1,2,3,4, Xin Ying1,2,3,4, Xiao-Xin Li6,7,8,9,10. 1. Department of Ophthalmology, Peking University People's Hospital, Beijing, China. 2. Eye Diseases and Optometry Institute, Beijing, China. 3. Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China. 4. College of Optometry, Peking University Health Science Center, Beijing, China. 5. Department of Ophthalmology, The Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong SAR, China. 6. Department of Ophthalmology, Peking University People's Hospital, Beijing, China. drlixiaoxin@163.com. 7. Eye Diseases and Optometry Institute, Beijing, China. drlixiaoxin@163.com. 8. Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China. drlixiaoxin@163.com. 9. College of Optometry, Peking University Health Science Center, Beijing, China. drlixiaoxin@163.com. 10. Xiamen Eye Center of Xiamen University, Xiamen, Fujian Province, China. drlixiaoxin@163.com.
Abstract
PURPOSE: To evaluate the functional and structural outcomes of intravitreal conbercept monotherapy using a "3 + pro re nata (PRN)" regimen in treatment-naïve subjects with polypoidal choroidal vasculopathy (PCV) up to 12 months. METHODS: Thirty subjects (30 eyes) with PCV participated in this interventional, retrospective study. All subjects received intravitreal injections of 0.5 mg (0.05 ml) conbercept using a "3 + PRN" regimen for 12 months. The changes in best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, polyp lesion area, and regression rate were evaluated at baseline, month 3, and month 12. RESULTS: At the study end-point, BCVA improved significantly from 52.80 ± 17.17 ETDRS letters at baseline to 62.20 ± 18.96 letters (P < 0.001), with a mean gain of 9.40 ± 14.97 letters. The central retinal thickness (CRT) significantly reduced from 454.93 ± 147.31 μm at baseline to 308.73 ± 106.80 μm (P < 0.001) at end-point, and the total macular volume (TMV) decreased from 9.51 ± 1.04 mm3 at baseline to 8.32 ± 0.84 mm3 at end-point (P < 0.001). The mean volume of pigment epithelial detachment (PED) decreased from 0.73 ± 0.97 mm3 at baseline to 0.48 ± 0.71 mm3 (P < 0.05) at month 3. At month 12, the mean volume of PED was 0.57 ± 0.80 mm3 (P > 0.05 compared to baseline). After the 3-monthly loading injections, 6 eyes (20.0%) showed complete polyp regression, whereas a total of 19 eyes (63.5%) showed complete regression at month 12. The average injections given per subject were 7.70 ± 1.81. CONCLUSION: Intravitreal conbercept using the "3 + PRN" regimen was effective in the treatment of PCV.
PURPOSE: To evaluate the functional and structural outcomes of intravitreal conbercept monotherapy using a "3 + pro re nata (PRN)" regimen in treatment-naïve subjects with polypoidal choroidal vasculopathy (PCV) up to 12 months. METHODS: Thirty subjects (30 eyes) with PCV participated in this interventional, retrospective study. All subjects received intravitreal injections of 0.5 mg (0.05 ml) conbercept using a "3 + PRN" regimen for 12 months. The changes in best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, polyp lesion area, and regression rate were evaluated at baseline, month 3, and month 12. RESULTS: At the study end-point, BCVA improved significantly from 52.80 ± 17.17 ETDRS letters at baseline to 62.20 ± 18.96 letters (P < 0.001), with a mean gain of 9.40 ± 14.97 letters. The central retinal thickness (CRT) significantly reduced from 454.93 ± 147.31 μm at baseline to 308.73 ± 106.80 μm (P < 0.001) at end-point, and the total macular volume (TMV) decreased from 9.51 ± 1.04 mm3 at baseline to 8.32 ± 0.84 mm3 at end-point (P < 0.001). The mean volume of pigment epithelial detachment (PED) decreased from 0.73 ± 0.97 mm3 at baseline to 0.48 ± 0.71 mm3 (P < 0.05) at month 3. At month 12, the mean volume of PED was 0.57 ± 0.80 mm3 (P > 0.05 compared to baseline). After the 3-monthly loading injections, 6 eyes (20.0%) showed complete polyp regression, whereas a total of 19 eyes (63.5%) showed complete regression at month 12. The average injections given per subject were 7.70 ± 1.81. CONCLUSION: Intravitreal conbercept using the "3 + PRN" regimen was effective in the treatment of PCV.
Authors: Luiz H Lima; Carl Schubert; Daniela C Ferrara; Joanna E Merriam; Yutaka Imamura; K Bailey Freund; Richard F Spaide; Lawrence A Yannuzzi; Rando Allikmets Journal: Ophthalmology Date: 2010-04-08 Impact factor: 12.079
Authors: Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Chui Ming Gemmy Cheung; Won Ki Lee; Hideki Koizumi; Kunal Dansingani; Timothy Y Y Lai; K Bailey Freund Journal: Eye (Lond) Date: 2018-07-11 Impact factor: 3.775